Publication: Papel del TLR4 plaquetario en el ictus
Loading...
Official URL
Full text at PDC
Publication Date
2021-07-23
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citations
Exportar
Abstract
El ictus es una de las enfermedades más prevalentes en el mundo, afectando a 15millones de personas cada año. Actualmente, para el ictus agudo, sólo existen dos tratamientos aprobados por la EMA y la FDA: la trombolisis farmacológica con t-PA (tissue-Plasminogen Activator por sus siglas en inglés) y la trombectomía mecánica. Sin embargo, estos tratamientos cuentan con grandes inconvenientes, entre ellos, la baja incidencia de reperfusión y el fenómeno de la transformación hemorrágica (TH) (Larrue et al., 1997; Kaesmacher et al., 2017).Actualmente se desconocen las causas de la no-reperfusión, pero se cree que la composición del trombo juega un papel importante, siendo el porcentaje de éxito, en el caso de los trombos ricos en plaquetas, de un 6% (Tomkins et al., 2015). De hecho, la composición del trombo ha sido de interés para la comunidad científica durante la última década, siendo los NETs (Neutrophil Extracellular Traps por sus siglas en inglés) el último componente en ser identificado (Gardiner & Andrews, 2012; Laridan et al.,2017)...
Stroke is one of the most prevalent diseases worldwide, affecting 15 million people every year. Only two treatment regimens are currently approved by the EMA and the FDA: pharmacological thrombolysis using t-PA (tissue plasminogen activator) and mechanical thrombectomy. Unfortunately, these two treatments have some limitations: a low rate of arterial recanalization and the phenomenon of hemorrhagic transformation (HT), among others (Larrue et al., 1997; Kaesmacher et al., 2017). On the one hand, the reasons of this non-reperfusion phenomenon are still unknown. However, considering that only 6% occlusive platelet-rich thrombi are successfully reperfused (Tomkins et al., 2015), it is believed that thrombus composition might have an important role on this process. In fact, during the last few years, scientists have been focused on this issue who have had identified a new thrombus component called NETs (Neutrophil Extracellular Traps) (Gardiner & Andrews, 2012; Laridan et al., 2017)...
Stroke is one of the most prevalent diseases worldwide, affecting 15 million people every year. Only two treatment regimens are currently approved by the EMA and the FDA: pharmacological thrombolysis using t-PA (tissue plasminogen activator) and mechanical thrombectomy. Unfortunately, these two treatments have some limitations: a low rate of arterial recanalization and the phenomenon of hemorrhagic transformation (HT), among others (Larrue et al., 1997; Kaesmacher et al., 2017). On the one hand, the reasons of this non-reperfusion phenomenon are still unknown. However, considering that only 6% occlusive platelet-rich thrombi are successfully reperfused (Tomkins et al., 2015), it is believed that thrombus composition might have an important role on this process. In fact, during the last few years, scientists have been focused on this issue who have had identified a new thrombus component called NETs (Neutrophil Extracellular Traps) (Gardiner & Andrews, 2012; Laridan et al., 2017)...
Description
Tesis inédita de la Universidad Complutense de Madrid, Facultad de Medicina, Departamento de Farmacología y Toxicología, leída el 29/10/2020